Buy AOD-9604

AOD-9604 (also known as AOD9604) is available directly from New-U Research Compounds at https://new-u.io/peptide/aod-9604. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

AOD-9604 starts at $33 for a 1-vial research pack (5mg per vial) at New-U Research Compounds, with 4 pack sizes available. Orders over $300 ship free.

Yes. Every AOD-9604 batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

AOD-9604 ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, AOD-9604 is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

AOD-9604, tyrosine-modified C-terminal HGH fragment (177-191) with β3-adrenergic receptor-mediated lipolysis and GRAS safety designation. New-U supplies AOD-9604 as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the AOD-9604 research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for AOD-9604 are described in research-model terms only. New-U Research Compounds supplies AOD-9604 strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Lyophilised AOD-9604 is reconstituted with bacteriostatic water — sterile water with 0.9% benzyl alcohol, the standard multi-use diluent for research peptides. New-U supplies USP-grade bacteriostatic water at https://new-u.io/peptide/bacteriostatic-water, and a free reconstitution calculator at https://new-u.io/tracker/calculator works out the volume for any peptide. Supplied for laboratory research only — not for human use.

Yes. AOD-9604 can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

AOD-9604 ships in 10-vial research packs as standard, in 4 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade AOD-9604, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/aod-9604.

AOD-9604 is a synthetic, tyrosine-modified version of the C-terminal lipolytic fragment of human growth hormone (Tyr-hGH 177-191) — closely related to native HGH Fragment 176-191, with an added N-terminal tyrosine for stability and lipolytic potency. It was developed to target fat metabolism without the growth or IGF-1 effects of full HGH, and reached Phase 2b human obesity trials. Supplied as a lyophilised research-grade powder for laboratory use only.

In research models AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis via a β3-adrenergic-linked mechanism, reportedly without raising IGF-1 or affecting blood glucose the way full HGH does. These are findings in cell and animal models; New-U supplies it for laboratory research only and implies no human effect.

Early and animal research showed lipolytic activity, but the Phase 2b human obesity trial did not produce statistically significant weight loss versus placebo. So its real-world efficacy is unproven, and it is sold as a research compound only — not an approved weight-loss drug.

For laboratory preparation, dissolve the lyophilised powder in bacteriostatic water: concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.

AOD-9604 is the same lipolytic fragment with a tyrosine substituted for the N-terminal phenylalanine. The tyrosine substitution improves stability and lipolytic potency and was the design choice that enabled the molecule to progress through formal clinical trials as a distinct research entity.

No - and this was a deliberate design goal. AOD-9604 does not bind the growth hormone receptor, so it does not trigger hepatic IGF-1 synthesis and does not produce the counter-regulatory insulin-opposing effects of full-length HGH. Clinical trials confirmed unchanged glycemic parameters.

The Phase 2b was an oral-dosing study at 0.25-1 mg/day, and those doses were likely too low to produce meaningful weight loss in humans - the earlier Phase 2a at different dosing had shown ~2.6 kg loss versus 0.8 kg placebo. The failure ended commercial development but did not change the preclinical mechanism data.

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The disulfide-containing cyclic structure is reasonably stable but plan usage within the normal peptide-handling window.